IN8bio (INAB)
NASDAQ:INAB
Top Page
IN8bio
(NASDAQ:INAB)
Select Model
Select Model
Rating:45Neutral
Price Target:
$1.50
▼(-6.83% Downside)
Action:ReiteratedDate:03/24/26
The score is held down primarily by weak financial performance (no revenue, ongoing losses, and negative free cash flow), with technicals also reflecting a continuing downtrend. Modest leverage and a constructive leadership move provide some support, but limited valuation visibility and ongoing funding risk keep the overall score low.
Positive Factors
Modest leverage, stronger balance sheet
IN8bio's low and improving leverage (debt≈$2.8M vs equity≈$27.6M; D/E ~0.10 in 2025) provides durable financial flexibility. Lower fixed obligations reduce solvency risk and extend runway for clinical programs, supporting execution while revenue remains absent.
Negative Factors
Pre-revenue with persistent losses
IN8bio remains a pre-revenue biotech with no product sales through 2025 and sizable operating losses. Long-term viability depends on clinical success and external funding; absent commercialization or partnership revenue, the company faces sustained profitability and cash-generation risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Modest leverage, stronger balance sheet
IN8bio's low and improving leverage (debt≈$2.8M vs equity≈$27.6M; D/E ~0.10 in 2025) provides durable financial flexibility. Lower fixed obligations reduce solvency risk and extend runway for clinical programs, supporting execution while revenue remains absent.
Read all positive factors
IN8bio (INAB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$15.85M
Dividend YieldN/A
Average Volume (3M)74.58K
Price to Earnings (P/E)―
Beta (1Y)1.65
Revenue GrowthN/A
EPS Growth70.57%
CountryUS
Employees18
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.45
Shares Outstanding9,847,089
10 Day Avg. Volume64,995
30 Day Avg. Volume74,576
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.37
Price to Sales (P/S)0.00
P/FCF Ratio-0.81
Enterprise Value/Market Cap-1.06
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit14.36
Enterprise Value/Ebitda0.97
Forecast
1Y Price Target
$5.00Price Target Upside210.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.72
Revenue Forecast (FY)N/A
IN8bio Business Overview & Revenue Model
Company Description
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified au...
How the Company Makes Money
As a clinical-stage biotechnology company, IN8bio does not have publicly established, recurring product revenue from commercialized therapies (null). Its funding and cash generation typically come from financing activities (e.g., issuing equity an...
IN8bio Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
58
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -2.50M | 0.00 | -2.50M | -1.10M | 0.00 |
| EBITDA | -17.36M | -26.94M | -27.51M | -27.42M | -13.87M |
| Net Income | -19.44M | -30.44M | -30.01M | -28.52M | -14.65M |
Balance Sheet | |||||
| Total Assets | 32.28M | 20.94M | 33.71M | 33.04M | 42.22M |
| Cash, Cash Equivalents and Short-Term Investments | 27.09M | 11.12M | 21.28M | 18.18M | 37.02M |
| Total Debt | 2.78M | 5.03M | 4.89M | 5.87M | 2.41M |
| Total Liabilities | 4.72M | 6.47M | 8.77M | 10.31M | 4.04M |
| Stockholders Equity | 27.56M | 14.48M | 24.94M | 22.73M | 38.18M |
Cash Flow | |||||
| Free Cash Flow | -12.71M | -24.25M | -23.94M | -27.83M | -13.82M |
| Operating Cash Flow | -12.71M | -24.15M | -23.34M | -24.12M | -13.51M |
| Investing Cash Flow | 0.00 | -187.00K | -600.00K | -3.71M | -309.00K |
| Financing Cash Flow | 28.64M | 14.18M | 27.04M | 8.99M | 32.95M |
IN8bio Technical Analysis
Negative
1.61
Price Trends
1.92
Negative
1.88
Negative
2.06
Negative
Market Momentum
-0.03
Positive
40.58
Neutral
32.15
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INAB, the sentiment is Negative. The current price of 1.61 is below the 20-day moving average (MA) of 1.79, below the 50-day MA of 1.92, and below the 200-day MA of 2.06, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 40.58 is Neutral, neither overbought nor oversold. The STOCH value of 32.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INAB.
IN8bio Risk Analysis
IN8bio disclosed 72 risk factors in its most recent earnings report. IN8bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
IN8bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $6.85M | -1.38 | -60.33% | ― | 13.30% | 22.70% | |
48 Neutral | $20.53M | -0.94 | -74.15% | ― | 6.29% | 7.42% | |
47 Neutral | $7.68M | -0.67 | -87.05% | ― | -62.75% | 23.87% | |
45 Neutral | $15.85M | -0.53 | -189.72% | ― | ― | 70.57% | |
44 Neutral | $5.45M | -0.27 | -334.42% | ― | ― | -228.89% |
* Healthcare Sector Average
INAB
IN8bio
1.61
-4.66
-74.32%
ERNA
Eterna Therapeutics
0.21
-3.23
-93.90%
QNRX
Quoin Pharmaceuticals
9.27
-1.05
-10.17%
XBIO
Xenetic Biosciences
2.99
-0.28
-8.56%
VYNE
VYNE Therapeutics
0.62
-1.09
-63.98%
APRE
Aprea Therapeutics
0.67
-1.57
-70.04%
IN8bio Corporate Events
Executive/Board Changes
IN8bio Announces Board Resignation and Interim Chair Appointment
Neutral
Feb 27, 2026
On February 26, 2026, IN8bio, Inc. announced that director Alan S. Roemer had notified the Board of his decision to resign from the Board and from the Audit and Compensation Committees, effective February 28, 2026. The company stated that his resi...
Business Operations and StrategyExecutive/Board Changes
IN8bio Elevates COO Kate Rochlin to President
Positive
Feb 9, 2026
On February 4, 2026, IN8bio’s board of directors appointed Chief Operating Officer Kate Rochlin as president, effective the same day, while she continues in her COO role. The appointment consolidates operational and strategic leadership unde...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.